Company Profile
Replimune Group Stock Price, News & Catalysts
- Ticker:
- REPL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
14.63 USD (-2.27%)
Close
Last updated: August 17, 2026
732M USD
Market cap
Why the stock is moving
The latest company update was “Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update”. REPL changed 1.45% and closed at $14.97 on Aug 14, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Oncolytic Immunotherapy Platform
Replimune develops engineered herpes-simplex-virus-based immunotherapies that selectively replicate within tumors, directly destroy cancer cells, release tumor antigens, and stimulate systemic antitumor immunity. Its viruses are armed with immune-activating components intended to enhance local tumor killing and complement checkpoint inhibitors.
TUDRIQEV
TUDRIQEV, previously known as RP1, is an FDA-approved oncolytic therapy encoding a fusogenic GALV-GP-R protein and GM-CSF. It is approved under the accelerated approval pathway in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on a PD-1 antibody-based regimen.
IGNYTE-3 Confirmatory Program
The global Phase 3 IGNYTE-3 study is evaluating TUDRIQEV plus nivolumab against physician's-choice therapy in advanced melanoma after anti-PD-1 treatment. The study is intended to verify clinical benefit and support continued approval, with overall survival as the primary endpoint.
RP2
RP2 builds on the same oncolytic HSV-1 backbone as TUDRIQEV and additionally expresses an anti-CTLA-4 antibody-like molecule. The design seeks to concentrate CTLA-4 blockade within tumors and tumor-draining lymph nodes while limiting systemic exposure.
Metastatic Uveal Melanoma
The registration-directed REVEAL study evaluates RP2 plus nivolumab against ipilimumab plus nivolumab in metastatic uveal melanoma. The Phase 2/3 trial uses overall survival and progression-free survival as primary endpoints.
Future catalysts
- US commercial launch of TUDRIQEV within 60 days of its August 6, 2026 FDA approval.
- Transition of the RP2 REVEAL study into Phase 3 in the first quarter of 2027.
- Primary overall-survival readout from the Phase 3 IGNYTE-3 confirmatory study in 2030.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Replimune Group (REPL)?
Replimune Group (REPL) most recently closed at 14.63 USD, a -2.27% move versus the previous session.
What is the market cap of Replimune Group (REPL)?
Replimune Group currently has a market capitalization of 732M USD on BioPharmSignal.
What does Replimune Group do?
Oncolytic Immunotherapy Platform Replimune develops engineered herpes-simplex-virus-based immunotherapies that selectively replicate within tumors, directly destroy cancer cells, release tumor antigens, and stimulate systemic antitumor immunity. Its viruses are armed with immune-activating components intended to enhance local tumor killing and complement...
On which exchange is REPL stock listed?
Replimune Group (REPL) is associated with NASDAQ, United States, Biopharma.
What is GALV-GP-R?
TUDRIQEV TUDRIQEV, previously known as RP1, is an FDA-approved oncolytic therapy encoding a fusogenic GALV-GP-R protein and GM-CSF.
Which conditions is Replimune Group targeting with GALV-GP-R?
Replimune Group is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Replimune Group describe recent progress with GALV-GP-R?
US commercial launch of TUDRIQEV within 60 days of its August 6, 2026 FDA approval. Transition of the RP2 REVEAL study into Phase 3 in the first quarter of 2027. Primary overall-survival readout from the Phase 3 IGNYTE-3 confirmatory study in 2030.
What is GM-CSF?
TUDRIQEV TUDRIQEV, previously known as RP1, is an FDA-approved oncolytic therapy encoding a fusogenic GALV-GP-R protein and GM-CSF.